Nontuberculous Mycobacterial Disease in Children - Epidemiology, Diagnosis & Management at a Tertiary Center.

Marc Tebruegge, Anastasia Pantazidou, Duncan MacGregor, Gena Gonis, David Leslie, Luigi Sedda, Nicole Ritz, Tom Connell, Nigel Curtis

Journal: PloS one 2016;11(1):e0147513

PMID: 26812154

Abstract

BACKGROUND

There are limited data on the epidemiology, diagnosis and optimal management of nontuberculous mycobacterial (NTM) disease in children.

METHODS

Retrospective cohort study of NTM cases over a 10-year-period at a tertiary referral hospital in Australia.

RESULTS

A total of 140 children with NTM disease, including 107 with lymphadenitis and 25 with skin and soft tissue infections (SSTIs), were identified. The estimated incidence of NTM disease was 0.6-1.6 cases / 100,000 children / year; no increasing trend was observed over the study period. Temporal analyses revealed a seasonal incidence cycle around 12 months, with peaks in late winter/spring and troughs in autumn. Mycobacterium-avium-complex accounted for most cases (77.8%), followed by Mycobacterium ulcerans (14.4%) and Mycobacterium marinum (3.3%). Polymerase chain reaction testing had higher sensitivity than culture and microscopy for acid-fast bacilli (92.0%, 67.2% and 35.7%, respectively). The majority of lymphadenitis cases underwent surgical excision (97.2%); multiple recurrences in this group were less common in cases treated with clarithromycin and rifampicin compared with clarithromycin alone or no anti-mycobacterial drugs (0% versus 7.1%; OR:0.73). SSTI recurrences were also less common in cases treated with two anti-mycobacterial drugs compared with one or none (10.5% versus 33.3%; OR:0.23).

CONCLUSIONS

There was seasonal variation in the incidence of NTM disease, analogous to recently published observations in tuberculosis, which have been linked to seasonal variation in vitamin D. Our finding that anti-mycobacterial combination therapy was associated with a reduced risk of recurrences in patients with NTM lymphadenitis or SSTI requires further confirmation in prospective trials.

Address: Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.; Infectious Diseases Unit, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.; Murdoch Children's Research Institute, Parkville, Victoria, Australia.; Academic Unit of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.; Department of Anatomical Pathology, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.; Department of Microbiology, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.; Mycobacterium Reference Laboratory, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia.; Department of Geography and Environment, University of Southampton, Southampton, United Kingdom.; Infectious Diseases Unit, University Children's Hospital Basel, Basel, Switzerland.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.